<DOC>
	<DOC>NCT02601313</DOC>
	<brief_summary>Study KTE-C19-102 is a phase 2, multicenter, open-label study evaluating the efficacy of KTE-C19 in subjects with Relapsed/Refractory MCL</brief_summary>
	<brief_title>A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<criteria>Key Pathologically confirmed MCL Up to 5 prior regimens for MCL. Prior therapy must have included: Anthracycline or bendamustinecontaining chemotherapy and AntiCD20 monoclonal antibody therapy and Ibrutinib Relapsed or refractory disease, defined by the following: Disease progression after last regimen, or Refractory disease is defined failure to achieve a PR or CR to the last regimen At least 1 measurable lesion according to the revised IWG Response Criteria for Malignant Lymphoma Age 18 years or older Eastern cooperative oncology group (ECOG) performance status of 0 or 1 ANC ≥ 1000/µL Platelet count ≥ 50,000/µL Adequate renal, hepatic, and cardiac function defined as: Serum creatinine ≤ 1.5 mg/dL Serum ALT/AST ≤ 2.5 ULN Total bilirubin ≤ 1.5 mg/dL, except in subjects with Gilbert's syndrome. Cardiac ejection fraction ≥ 50% (by ECHO) and no evidence of pericardial effusion as determined by an ECHO. Key History of malignancy other than nonmelanomatous skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years History of allogeneic stem cell transplantation Prior CD19 targeted therapy Prior CAR therapy or other genetically modified T cell therapy Known history of infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus (antiHCV positive) Subjects with detectable cerebrospinal fluid malignant cells or brain metastases or with a history of cerebrospinal fluid malignant cells or brain metastases History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>